Horse Anti-Thymocyte Globulin (hATG)
Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 140 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- White Blood Cell Stimulant, Steroid
- Trial Type
- Treatment
- Last Update
- 3 weeks ago
- SparkCures ID
- 1504
- NCT Identifier
- NCT01624805
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.